TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18164847

Group type: EXPERIMENTAL
Intervention: WBRT and thalidomide
Number of subjects: 332

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 332
Study: 15936184

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formoterol 18 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formoterol/budesonide combination 9/320 microg
Number of subjects: 30
Study: 14668418

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 29162214

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/ezetimibe fixed-dose combination (FDC; 10 mg/10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin/ezetimibe single agents (10 mg/10 mg)
Number of subjects: 0
Study: 9094892

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (294 mg vitamin E, 1000 mg vitamin C, and 60 mg ubiquinone daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 8
Study: 7901257

Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3541168

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Clinoril (sulindac)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clinoril and Placebo
Number of subjects: 110
Study: 31184796

Group type: EXPERIMENTAL
Intervention: Open-ended group intervention based on a cognitive behavioural therapy for insomnia self-help book
Number of subjects: 40

Group type: COMPARATOR
Intervention: Care as usual/wait-list control condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of the book and the open-ended group intervention
Number of subjects: 40
Study: 30134847

Group type: EXPERIMENTAL
Intervention: Hemocontrol hemodialysis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 29
Study: 27780198

Group type: EXPERIMENTAL
Intervention: Intensive intervention (IPC, MM, CM, PA)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard nutrition counseling with less intensive MM, CM, and PA
Number of subjects: 500
Study: 24285284

Group type: EXPERIMENTAL
Intervention: Udenafil 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22933818

Group type: EXPERIMENTAL
Intervention: Frightening music
Number of subjects: 10
Study: 20830219

Group type: EXPERIMENTAL
Intervention: EPBD with long ballooning time (60 seconds)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EPBD with short ballooning time (20 seconds)
Number of subjects: 70
Study: 18162935

Group type: COMPARATOR
Intervention: Killed oral cholera vaccine (mass immunization of older children and adults)
Number of subjects: 89596

Group type: COMPARATOR
Intervention: Vaccine coverage of adult women
Number of subjects: 89596
Study: 16416356

Group type: EXPERIMENTAL
Intervention: Neuropsychological training programme (12 sessions over 4 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neuropsychological training programme
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 12524408

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11961609

Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller's myotomy and Dor's fundoplication
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endoscopic dilation
Number of subjects: 30
Study: 10430720

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cycle Ergometry Training (CET)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CET + IMT
Number of subjects: 53

Group type: COMPARATOR
Intervention: Health Education (ED)
Number of subjects: 53
Study: 7477166

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (liothyronine sodium) administered as an intravenous bolus of 0.8 microgram per kilogram of body weight and then as an infusion of 0.113 microgram per kilogram per hour for six hours
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 2401187

Group type: EXPERIMENTAL
Intervention: Lornoxicam (4 mg as a film-coated tablet) alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Maalox (10 ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Solugastril (10 g)
Number of subjects: 18
Study: 7322722

Group type: EXPERIMENTAL
Intervention: Mailed reminders
Number of subjects: 766

Group type: COMPARATOR
Intervention: No mailed reminders (Control)
Number of subjects: 766
Study: 6381007

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) at 1.00 +/- 0.06 U insulin/h from 10 p.m. to 8 a.m.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Interruption of insulin infusion between 11 p.m. and 1 a.m.
Number of subjects: 7
Study: 28857811

Group type: EXPERIMENTAL
Intervention: Urinary biomarker‐triggered KDIGO care bundle (early optimization of fluid status, maintenance of perfusion pressure, discontinuation of nephrotoxic agents)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Urinary biomarker‐triggered KDIGO care bundle
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard intensive care unit (ICU) care
Number of subjects: 121
Study: 27788811

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (50 mg/kg) administered in the last 30 minutes of the operation.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (normal magnesium level).
Number of subjects: 70
Study: 24709780

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 60
Study: 22450429

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 4819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: CYP2C19 gain-of-function alleles
Number of subjects: 4819
Study: 20055981

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel (CP) - carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21
Number of subjects: 189

Group type: COMPARATOR
Intervention: Carboplatin plus pegylated liposomal doxorubicin (CLD) - carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel (CP)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Carboplatin plus pegylated liposomal doxorubicin (CLD)
Number of subjects: 189
Study: 18076334

Group type: EXPERIMENTAL
Intervention: Amiodarone plus AFP retention
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Amiodarone without AFP retention
Number of subjects: 178

Group type: COMPARATOR
Intervention: AFP retention alone
Number of subjects: 178

Group type: COMPARATOR
Intervention: AFP removal alone
Number of subjects: 178

Group type: COMPARATOR
Intervention: AFP removal plus amiodarone
Number of subjects: 178
Study: 17046767

Group type: EXPERIMENTAL
Intervention: Bedding control instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12566175

Group type: EXPERIMENTAL
Intervention: L-365,260 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: L-365,260 120 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10942920

Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tendency toward overeating
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Restraint
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: DEBQ disinhibition scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TFEQ disinhibition scale
Number of subjects: 200
Study: 8820894

Group type: EXPERIMENTAL
Intervention: isoenergetic low-carbohydrate (CHO) diet [7.8 (0.6)% total energy intake, n = 6]
Number of subjects: 11

Group type: COMPARATOR
Intervention: isoenergetic high-CHO diet [81.5 (0.4)%, n = 5]
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: low-CHO diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: high-CHO diet
Number of subjects: 11
Study: 1579623

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3907395

Group type: EXPERIMENTAL
Intervention: Enprofylline 1.5 mg/kg b.wt.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theophylline 5 mg/kg b.wt.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31740443

Group type: EXPERIMENTAL
Intervention: 8 weeks of PNS (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 4 weeks of placebo followed by 4 weeks of PNS (group 2)
Number of subjects: 28
Study: 30314913

Group type: COMPARATOR
Intervention: two doses of 9vHPV
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 2vHPV
Number of subjects: 371

Group type: COMPARATOR
Intervention: 9vHPV
Number of subjects: 371
Study: 27622956

Group type: EXPERIMENTAL
Intervention: Iontophoretic SM injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 40
Study: 24576885

Group type: EXPERIMENTAL
Intervention: PCV13 with aluminum phosphate (AlPO 4)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCV13 without aluminum phosphate (AlPO 4)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCV13/PCV13
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23/PCV13
Number of subjects: 105

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 105
Study: 22321874

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle modification program
Number of subjects: 107
Study: 20051587

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200-mg tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: tramadol IR 50-mg tablets
Number of subjects: 0
Study: 18719632

Group type: EXPERIMENTAL
Intervention: CM3 (six capsules taken 30 min before a standardized solid meal)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (matching placebo taken 30 min before a standardized solid meal)
Number of subjects: 19
Study: 15813665

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/100 microg twice daily
Number of subjects: 725

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily plus oral montelukast 10mg daily
Number of subjects: 725
Study: 12616010

Group type: EXPERIMENTAL
Intervention: Covered nitinol stent (n = 33)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Polyurethane stent (n = 35)
Number of subjects: 68
Study: 11128259

Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Number of subjects: 107

Group type: COMPARATOR
Intervention: Current practice (control)
Number of subjects: 107
Study: 8971297

Group type: COMPARATOR
Intervention: 30 mg topical pharyngeal lidocaine spray
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 100 mg topical pharyngeal lidocaine spray
Number of subjects: 114
Study: 1629066

Group type: EXPERIMENTAL
Intervention: T3 (30 micrograms/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6713905

Group type: EXPERIMENTAL
Intervention: chenodiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29331036

Group type: EXPERIMENTAL
Intervention: High miR-21 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low PDCD4 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-21 and PDCD4 expression levels
Number of subjects: 0
Study: 28500254

Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg BID for normal renal function, 75 mg BID for impaired renal function)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 30
Study: 26318836

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 24195965

Group type: EXPERIMENTAL
Intervention: Web-based intervention (Philips DirectLife)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 235
Study: 21447137

Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lingual infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buccal infiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lingual infiltration
Number of subjects: 20
Study: 19004194

Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral Hegu (LI 4) plus intravenous dripping of oxytocin
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intravenous dripping of oxytocin
Number of subjects: 276
Study: 16645295

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer (HHD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biodex dynamometer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Classification of individuals into tertiles of muscle strength
Number of subjects: 20
Study: 14520257

Group type: EXPERIMENTAL
Intervention: 3 servings/day of 1% fluid milk (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Juice not fortified with calcium (n=14)
Number of subjects: 28
Study: 10795744

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg QAM
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg QAM
Number of subjects: 243

Group type: COMPARATOR
Intervention: Omeprazole 20 mg QAM
Number of subjects: 243
Study: 8699239

Group type: EXPERIMENTAL
Intervention: 11C‐methionine (MET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 82Rubidium (RUB)
Number of subjects: 30
Study: 1740204

Group type: EXPERIMENTAL
Intervention: Protocol A (menotropins)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Protocol B (GnRH agonist)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Clinical pregnancies
Number of subjects: 67
Study: 6392167

Group type: EXPERIMENTAL
Intervention: 12% Hexabrix
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 16% Hexabrix
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 8% Hexabrix
Number of subjects: 26
Study: 31259616

Group type: EXPERIMENTAL
Intervention: En masse retraction (ER)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Two-step retraction (TSR)
Number of subjects: 48
Study: 29666295

Group type: EXPERIMENTAL
Intervention: Lung ultrasound performed before spontaneous breathing trial (SBT)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Successful SBT
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: B-pattern detected by lung ultrasound
Number of subjects: 250
Study: 26344351

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy with endometrial scratch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office hysteroscopy
Number of subjects: 0
Study: 23925924

Group type: EXPERIMENTAL
Intervention: EXTRA program (4 sessions of 1-hour group education, self-management, and global upper extremity exercise training, supplementing a 12-week individualized home exercise regimen)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 22933790

Group type: EXPERIMENTAL
Intervention: Estimated white matter tract strength in the premotor cortex seeded from the posterior putamen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimated tract strength in the ventromedial prefrontal cortex seeded from the caudate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gray matter density in the posterior putamen
Number of subjects: 0
Study: 20137647

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + surgical resection (CS group)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Surgical resection alone (S group)
Number of subjects: 117
Study: 17583029

Group type: EXPERIMENTAL
Intervention: 2004 survey respondents
Number of subjects: 0
Study: 15129393

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-weight-bearing exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control program (no intervention)
Number of subjects: 120
Study: 11471078

Group type: EXPERIMENTAL
Intervention: Rapid assessment protocol examining active trachoma in children
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Rapid assessment protocol examining trichiasis in women
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Rapid assessment method
Number of subjects: 1161
Study: 9531580

Group type: EXPERIMENTAL
Intervention: low-dose IFN-alpha2b (3 MIU, 5 days/week)
Number of subjects: 195

Group type: COMPARATOR
Intervention: hydroxyurea alone (control group)
Number of subjects: 195
Study: 8554248

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 400 IU in one tablet daily
Number of subjects: 2578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2578
Study: 2230239

Group type: EXPERIMENTAL
Intervention: Silver oxide-coated urinary catheter
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control silicone catheter
Number of subjects: 482
Study: 425129

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 233
Study: 30862225

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 23
Study: 27693438

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine for cord care
Number of subjects: 36911

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 36911
Study: 24330983

Group type: EXPERIMENTAL
Intervention: 10% glucose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 25% glucose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 50% glucose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 12% sucrose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 24% sucrose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 30% sucrose
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Sucrose groups (12%, 24%, 30%)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Glucose groups (10%, 25%, 50%)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Oxygen saturation decrease
Number of subjects: 560
Study: 21685798

Group type: EXPERIMENTAL
Intervention: Baseline co-worker social support
Number of subjects: 1240
Study: 19370185

Group type: EXPERIMENTAL
Intervention: Nimulid (N) 100 mg 2 x/day for 20 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tenaprost (T) 100 mg 2 x/day for 20 days
Number of subjects: 60
Study: 16443872

Group type: EXPERIMENTAL
Intervention: Model Predictive Control (MPC) algorithm (n = 30, target range 80-110 mg/dl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Model Predictive Control (MPC) algorithm (n = 16)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine glucose management protocols (n = 30, control group)
Number of subjects: 60
Study: 15565893

Group type: EXPERIMENTAL
Intervention: Medikinet-Retard (long-acting methylphenidate)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 11780205

Group type: EXPERIMENTAL
Intervention: Lenograstim stimulated donor marrow (3-4 micrograms.kg-1.d-1 for seven days prior to marrow harvest)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lenograstim stimulated donor marrow
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (donors without G-CSF)
Number of subjects: 30
Study: 9663838

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m., clarithromycin 250 mg b.d. and amoxycillin 500 mg b.d. (OAC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.m., metronidazole 400 mg b.d. and clarithromycin 250 mg b.d. (OMC)
Number of subjects: 82
Study: 1318742

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine (group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cisplatin, vinblastine and mitomycin (group B)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine (group A) or Cisplatin, vinblastine and mitomycin (group B)
Number of subjects: 103
Study: 2859781

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Acebutolol with diuretic
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo with diuretic
Number of subjects: 360
Study: 31584836

Group type: EXPERIMENTAL
Intervention: Neural network model
Number of subjects: 8956

Group type: COMPARATOR
Intervention: Rule-based model
Number of subjects: 8956
Study: 29326295

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27085565

Group type: EXPERIMENTAL
Intervention: Exercise intervention (6 months intensive exercise program under supervision)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin C intervention (1,000 mg every other day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (50 men with normal spermogram)
Number of subjects: 200
Study: 24641937

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy (GFFC) + Enoxaparin (40 mg daily)
Number of subjects: 19
Study: 22037124

Group type: EXPERIMENTAL
Intervention: rTMS (1 Hz stimulation for 10 days)
Number of subjects: 7
Study: 20028599

Group type: EXPERIMENTAL
Intervention: Concord grape juice supplementation for 12 weeks
Number of subjects: 12
Study: 17662156

Group type: EXPERIMENTAL
Intervention: Community based nurse assessment of falls and fracture risk factors, home hazards, referral to appropriate community interventions, and strength and balance exercise programme.
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care and social visits.
Number of subjects: 312
Study: 16037104

Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix daily (0.25 mg each, n = 37)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix every other day (0.25 mg each, n = 36)
Number of subjects: 73